TY - JOUR
T1 - Post-traumatic headache
T2 - epidemiology and pathophysiological insights
AU - Ashina, Håkan
AU - Porreca, Frank
AU - Anderson, Trent
AU - Mohammad Amin, Faisal
AU - Ashina, Messoud
AU - Winther Schytz, Henrik
AU - Dodick, David W.
N1 - Funding Information:
F.M.A. is a lecturer or scientific adviser for Novartis and Teva. M.A. is a consultant, speaker or scientific adviser for Alder, Allergan, Amgen, Eli Lilly, Novartis and Teva. H.W.S. is a lecturer for Novartis. D.W.D. reports the following competing interests: personal fees from Alder, Allergan, Amgen, Association of Translational Medicine, Autonomic Technologies, Aural Analytics, Biohaven, Charleston Laboratories, Daniel Edelman, Axsome, Dr Reddy’s Laboratories/Promius, Electrocore, Eli Lilly, eNeura, Foresite Capital, Impel, Ipsen, Neurolief, Nocira, Novartis, Oppenheimer, PSL Group Services, Satsuma, Sun Pharma (India), Supernus, Teva, Theranica, University of British Columbia, University Health Network, Vedanta, WL Gore, XoC, Zosano and ZP Opco; CME fees or royalty payments from Academy for Continued Healthcare Learning, Cambridge University Press, Chameleon, Global Access Meetings, Global Life Sciences, Global Scientific Communications, Haymarket, Healthlogix, Medicom Worldwide, Medlogix Communications, Mednet, Miller Medical, Oxford University Press, PeerView, Universal Meeting Management, UpToDate (Elsevier), WebMD Health/Medscape and Wolters Kluwer Health; stock options with Aural Analytics, Epien, GBS/Nocira, Healint, King-Devick Technologies, Matterhorn/Ontologics, Second Opinon/Mobile Health and Theranica; consulting without fee for Aural Analytics, Epien, Healint and Second Opinion/Mobile Health; position on the board of directors for Epien, King-Devick Technologies and Matterhorn/Ontologics; patent 17189376.1-1466: vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee; research funding from American Migraine Foundation, Henry Jackson Foundation, Patient-Centered Outcomes Research Institute and US Department of Defence; professional society fees or reimbursement for travel from American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, Canadian Headache Society and International Headache Society; and use agreement through employer for Myndshft. The other authors declare no competing interests.
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Post-traumatic headache (PTH) is a highly disabling secondary headache disorder and one of the most common sequelae of mild traumatic brain injury, also known as concussion. Considerable overlap exists between PTH and common primary headache disorders. The most common PTH phenotypes are migraine-like headache and tension-type-like headache. A better understanding of the pathophysiological similarities and differences between primary headache disorders and PTH could uncover unique treatment targets for PTH. Although possible underlying mechanisms of PTH have been elucidated, a substantial void remains in our understanding, and further research is needed. In this Review, we describe the evidence from animal and human studies that indicates involvement of several potential mechanisms in the development and persistence of PTH. These mechanisms include impaired descending modulation, neurometabolic changes, neuroinflammation and activation of the trigeminal sensory system. Furthermore, we outline future research directions to establish biomarkers involved in progression from acute to persistent PTH, and we identify potential drug targets to prevent and treat persistent PTH.
AB - Post-traumatic headache (PTH) is a highly disabling secondary headache disorder and one of the most common sequelae of mild traumatic brain injury, also known as concussion. Considerable overlap exists between PTH and common primary headache disorders. The most common PTH phenotypes are migraine-like headache and tension-type-like headache. A better understanding of the pathophysiological similarities and differences between primary headache disorders and PTH could uncover unique treatment targets for PTH. Although possible underlying mechanisms of PTH have been elucidated, a substantial void remains in our understanding, and further research is needed. In this Review, we describe the evidence from animal and human studies that indicates involvement of several potential mechanisms in the development and persistence of PTH. These mechanisms include impaired descending modulation, neurometabolic changes, neuroinflammation and activation of the trigeminal sensory system. Furthermore, we outline future research directions to establish biomarkers involved in progression from acute to persistent PTH, and we identify potential drug targets to prevent and treat persistent PTH.
UR - http://www.scopus.com/inward/record.url?scp=85072716724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072716724&partnerID=8YFLogxK
U2 - 10.1038/s41582-019-0243-8
DO - 10.1038/s41582-019-0243-8
M3 - Review article
C2 - 31527806
AN - SCOPUS:85072716724
SN - 1759-4758
VL - 15
SP - 607
EP - 617
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 10
ER -